Amvuttra (vutrisiran) is an approved treatment for FAP and other types of ATTR amyloidosis. Amvuttra targets faulty mRNA, the intermediate messenger molecule between the TTR gene and transthyretin protein. It eases the symptoms of neuropathy, or those resulting from the nerve damage that marks the disease.
Onpattro (patisiran) is an approved treatment for FAP that uses a technology researchers call RNA interference, or RNAi. Onpattro consists of lipid nanoparticles that contain siRNA. The nanoparticles deliver the siRNA to liver cells, where they significantly lower the expression of the faulty TTR gene.
Tegsedi (inotersen) is approved to treat adults with FAP. It is a once-weekly injection administered under the skin, or subcutaneously. Tegsedi is designed to interfere with the production of TTR and prevent the buildup of amyloid deposits.
Occupational therapy can help patients with neuropathies such as FAP in their daily lives. Occupational therapists work with patients and their communities to enable them to cope with the disease and help make the working environment more conducive for their specific needs.
Physiotherapy, also known as physical therapy, is the use of techniques to improve movement and function and restore the overall well-being of the body through rehabilitation, exercise, and advice. Physiotherapy can help alleviate some of the pain and restricted movement associated with peripheral neuropathy.
A liver transplant is the process of surgically replacing an unhealthy liver with a complete or partial healthy liver from a donor. Performing a liver transplant can greatly slow the progression of FAP by preventing the formation of defective TTR protein.
Wainua (eplontersen) is an under-the-skin, or subcutaneous, injectable therapy approved in the U.S. for adults with FAP. Designed to prevent nerve damage and thereby slow or halt disease progression, it is the first and only approved FAP therapy that can be self-administered by patients through an autoinjector.